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Introduction: One of the bacterial agents that has been found to be associated with colorectal cancer is
Streptococcus bovis, with 13% of infective endocarditis cases caused by this pathogenic species.
Case presentation: We describe the case of a 57-year-old Caucasian man with infiltrating and ulcerating metastatic
adenocarcinoma of the sigmoid colon. The patient was receiving second-line chemotherapy treatment and, on the
eighth day of the second cycle, he developed a grade IV pancytopenia. We diagnosed a severe sepsis with positive
blood cultures for Streptococcus bovis/gallolyticus with a secondary endocarditis.
Conclusions: A recent study suggests that the majority of patients affected by colonic cancer have a Streptococcus
bovis/gallolyticus colonization that becomes apparent as an overt infection only when immunosystem disorders or
cardiac valve lesions occur. This correlation is important for involving more specialists in a correct and early
diagnosis of this rare, but potentially fatal, complication.
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The human gastrointestinal tract is colonized by different
commensal bacterial species. This bacterial population
prevents the invasion of pathogenic bacteria [1].
Among the commensal bacteria, Streptococcus bovis
(S. bovis) is found in 2.5 to 15% of the population. Several
studies have shown a correlation between the presence of
S. bovis biotype I bacteremia and colon cancer.
In addition, 13% of infective endocarditis cases are
caused by this pathogenic species [2,3].
The aim of this report is to present the clinical, diagnostic,
and therapeutic aspects of a patient with advanced colon
cancer who developed secondary neutropenia after antineo-
plastic treatment with subsequent onset of meningo-
encephalitis and endocarditis related to S. bovis/gallolyticus
infection.
The clinical, diagnostic and therapeutic aspects will be
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A 57-year-old Caucasian man with no family history
of neoplastic diseases and no comorbidities, after
severe weight loss and abdominal pain, was exam-
ined by his general practitioner for tumor markers
(carcinoembryonic antigen (CEA)=4448 and cancer antigen
(CA)19.9=4728). His fecal occult blood test was positive
and the biopsies obtained during a colonoscopy were
positive for infiltrating and ulcerated poorly differentiated
adenocarcinoma (G3) of the sigmoid colon.
An immunohistochemistry analysis revealed epider-
mal growth factor receptor (EGFR) positivity and mo-
lecular analysis showed that both KRAS and BRAF were
not mutated.
A staging computed tomography (CT) scan showed liver,
lung, and spleen metastases and the presence of peritoneal
carcinomatosis. Because of the advanced stage of disease,
no indication was given for surgical treatment. The patient
underwent 10 cycles of chemotherapy according to the
FOLFOX6 regimen (oxaliplatin 100mg/mq; leucovorin
400mg/mq; 5-fluorouracil 400mg/mq bolus followed by
5-fluorouracil 2400mg/mq by continuous infusion over
46 hours every two weeks) with markers reductiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Endocardial vegetation stack on the right
coronary cusp.
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status and weight gain. His chemotherapy treatment
was continued with capecitabine, 1000mg/mq twice a
day, as a maintenance therapy for two additional months.
After this treatment, a CT scan showed progression
of the disease in the lungs and liver, and laboratory
examinations showed an increase in the tumor markers
(CEA=820 and CA19.9=507).
The patient started a second-line chemotherapy with
cetuximab, 400mg/mq loading dose, and irinotecan
200mg/mq. On the eighth day of the second cycle the
patient developed fever (39°C), diarrhea, and confusion
and the neurological examination by the emergency
service revealed severe opisthotonus and retroversion
of the eyes. A brain CT scan was negative for ischemic
events or secondary lesions and his electroencephalogram
(EEG) was normal.
In the afternoon, the patient was admitted to the medical
oncology unit, where he was diagnosed with severe sepsis
with clinical involvement of the meningoencephalic system
and grade IV pancyopenia (hemoglobin (Hb)=8.5g/dL, red
blood cells (RBC)=2.8×10^6/mL, platelets (PLT)=31000mL,
white blood cells (WBC)=300mL, neutrophils=100mL).
While waiting for blood culture results, he started
empiric antibiotic therapy with 500mg levofloxacin ad-
ministered intravenously every 12 hours and 200mg
intravenous fluconazole once a day in association with
granulocyte colony-stimulating factor (G-CSF). After
five days, the pancytopenia resolved but the neurological
disorder persisted.
In the meantime, Streptococcus gallolyticus subsp
gallolyticus was isolated in the blood cultures. Echocardi-
ography showed a moderate aortic valve insufficiency due
to an endocardial vegetation stack on the right coronary
cusp (about 10mm in diameter) protruding in the outflow
tract of the left ventricle (Figure 1). A cerebrospinal fluid
sample was not taken due to the very low platelet count
(5000/mL on the second day after admission).
Ampicillin and sulbactam (3g intravenous every six hours)
were added to the antibiotic treatment.
On the fourteenth day, the patient’s neurological status
improved and he exhibited only residual mild opisthotonus
with no cognitive deficit.
A total body CT scan was performed on the third
week after admission, which showed progressive disease,
thus antineoplastic therapy was ceased.
Discussion
The incidence of colon cancer with S. bovis endocarditis
has been shown to be between 18 and 62% [4-10].
The co-occurrence of a bacterial endocarditis and
colon carcinoma was first reported in 1951 [11] but the
association of S. bovis and colorectal neoplasia was not
recognized until 1974 [12]. S bovis was documented byKlein et al. as the pathogenic agent specifically related
to the presence of a colon cancer in 1977 [13].
Bacteria are linked to cancer by two mechanisms:
chronic inflammation and the production of carcinogenic
metabolites [14].
S. bovis/gallolyticus has been reported to increase the
production of inflammatory cytokines in the colonic mu-
cosa of rats, suggesting a direct interaction between S.
bovis and colonic mucosal cells, which is thought to lead
to the development of colorectal cancer. It should be
noted that in humans most colonic neoplasms associated
with S. bovis bacteremia are ulcerated adenomas, a well-
known precursor of invasive cancer [15-19].
In our clinical case, the neoplastic disease was already
present when the patient developed bacteremia and
endocarditis secondary to the infection with S. bovis.
The infection occurred in the context of severe neutro-
penia. We assume that due to the critical condition of
the patient, he developed endocarditis and possibly a
meningoencephalitis as a result of the transition of the
S. bovis/gallolyticus through the ulcerated tumoral lesion
of the colon into the bloodstream.
A recent study suggested that the majority of patients
affected by colonic cancer develop a silent infection, but
it becomes apparent when immunosystem disorders or
cardiac valve lesions occur [20].
Considering the correlation between S. bovis/gallolyticus,
endocarditis and tumors, colorectal endoscopic evaluation
would be useful in patients who have developed bacterial
endocarditis caused by S. bovis/gallolyticus in order to
identify silent colorectal cancer as early as possible.
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In these cases, the teamwork of several specialists
(cardiologist, infectivologist, endoscopist, oncologist)
remains the gold standard for an accurate diagnostic
workup and prompt treatment decisions.
Therefore, understanding whether other cases like
ours have occurred and what to do in such situations
would be helpful.
In addition, the peculiar aspect of this case is the
presence of a neurological involvement, which could be
due to both the septic status and to a specific sensibility of
the brain membrane to Streptococcus bovis/gallolyticus,
albeit a cerebrospinal fluid (CSF) analysis was not done.
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